ETFDH

Across TCGA pan-cancer cohorts, ETFDH mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ETFDH data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ETFDH mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ETFDH expression acts as an unfavorable survival marker, although some lineages such as COAD and UCEC show a favorable association.

PDAC, COAD, and LSCC are the cancer types where ETFDH mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	IV	0.443	0.973	.024	9	view →
COAD	DFS	Median	III,IV	1.000	0.831	.027	6	view →
LSCC	DFS	Median	All	0.628	0.786	.041	3	view →
UCEC	DFS	Quartile	All	0.969	0.854	.042	2	view →
HNSC	DFS	Quartile	III,IV	1.000	0.361	.036	2	view →
CCRCC	OS	Tertile	All	1.000	0.708	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ETFDH–PDAC (OS)

Open the PDAC breakdown →